Dr. Reddy’s Laboratories Limited (REDY) – Pricing pressures and increasing cost of sales

RDY launched four products in the U.S., including Icosapent Ethyl Capsules, Ertapenem Injection, Sapropterin 100 milligram sachet, and Albendazole Tablets and relaunched Famotidine Tablets.

Highlights 

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– DCF Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages : 35